Provides NGS data analysis and interpretation for WGS, WES, and Gene-panels

Accelerates the diagnostic process from the raw genetic data to the clinical report

Provides Genomic and Clinical Cohort Analysis

Promotes a world with zero undiagnosed diseases

NGS ANALYSIS PLATFORM

Better Data for Better Health

Every patient deserves to be diagnosed and treated with the value of genomics and genetics knowledge. By working with physicians and hospital labs around the world, Geneyx offers a superior NGS data analysis and interpretation platform for WGS, WES, and Gene-Panels to scale clinical solutions to the global healthcare community. Our AI-based analysis platform significantly improves the diagnostics process, from the raw genetic data to the final clinical report. Geneyx promotes a world with zero undiagnosed diseases.

From NGS data analysis to drug discovery

Accelerating Genetic Diagnosis and Research

Geneyx Analysis

AI-Based Genetic Data Analysis

Geneyx Clinical Apps

Ready-To-Use Genetic Apps

Geneyx Research

Targeted Drug Discovery

Cases Analyzed

99500

Active Users

Countries

Citations

GENEYX ANALYSIS

For Hospitals & Labs

GENEYX ANALYSIS

For Hospitals & Labs

Knowledgebase

Dozens of Key Data Sources

Integrating dozens of key data sources, the Knowledgebase empowers your Next Generation Sequencing analysis by highlighting associations between genes and phenotypes, providing supporting evidence for immediate evaluation, and automatically generating case reports.

Rapid and accurate phenotype-driven variant prioritization, supporting protein-coding genes and regulatory regions

Leveraging leading integrated regulatory region database.

Enabling rapid evaluation of candidate mutations and automated population of customized reports

Routinely updated with cutting-edge tools and the most recent, relevant data sources

Success Stories

See Geneyx In Action

Identifying multi-nucleotide variants associated with congenital hypotonia and global developmental delay

WGS identified a likely pathogenic, de novo variant in POLR2A, which has a strong association with the phenotype displayed by the individual. The variant was adjacent to a polymorphism variant that was inherited from one of the parents, and this caused their in-house pipeline to mis-identify it as an inherited MNV in the exome sequencing analysis. The WGS findings led to a positive finding that could be presented to the patient.

Identifying a unique novel genetic event for juvenile Parkinson

With their current platform, they achieve a diagnostic yield of approximately 50%, and for the remaining undiagnosed cases, they choose to implement Geneyx Analysis. One complex case they encountered was a large family presenting with early onset Parkinson’s disease (Juvenile Parkinson), which affected several siblings born to closely related parents. The team had sent 10 samples for exome sequencing, which was the standard and most comprehensive genetic test available for clinical diagnostics. However, the results from exome sequencing were inconclusive, so they implemented whole genome sequencing on a subset of the family and analyzed the data with Geneyx.

Identifying novel mutations responsible for colon cancer predisposition

Prof Revital Kariv, M.D., and her team diagnose and treat patients with colon cancer. In many cases, they identify families with a clear predisposition to develop polyposis and thereafter colon cancer quite early in their lives, implying a strong inherited genetic background for the trait.

Increasing the accuracy and decreasing the time required for clinical genetic analysis

In 2017, The genetic team at the largest pediatric hospital in Europe, Prof Antonio Novelli and his team of geneticists used to analyze dozens of rare genetic disorder cases per month.

Our Customers' Experience

In Their Own Words

“Geneyx Analysis is at the highest level, and with extraordinary bioinformatics pipelines”

“The Geneyx platform for genetic analysis is at the highest level, and with extraordinary bioinformatic pipelines. Geneyx will assist us in making impactful discoveries for gene-elusive sudden death arrhythmia syndromes.”

Michael Gollob, MD, FRCPC

Scientist, Toronto General Hospital Research Institute (TGHRI)

Toronto, Canada

“I am writing to recommend the services of Geneyx analysis platform”

“I am writing to recommend the services of Geneyx analysis platform. I have been using the Geneyx Analysis platform for the last 4 years to analyze genetic data from ~700 children with rare disorders including from the Department of Pediatrics and Adolescent Medicine using Whole Exome Sequencing and, most recently, Whole Genome Sequencing. They have been reasonably priced and willing to provide great customer service in a timely manner. I am happy to recommend the service of the Geneyx Analysis platform.”

Dr. Brian Chung

Clinical Associate Professor, Department of Pediatrics and Adolescent Medicine

Li Ka shing Faculty of Medicine The University of Hong Kong

“A very cost-effective tool in our hands”

“We have been using the Geneyx software for the last 2 years. We have analyzed for clinical purposes a total of approximately 1000 NGS sequences of exomes (WES) and genomes (WGS). We are very satisfied with the Geneyx software as it is easy to use and provides a ranking of variants as a cause of the patients’ phenotype that we have found to be very informative. This ranking allows an easy screening for causing variants which saves analysis time and increases the diagnostic yield. This last point, together with the actual cost per sample results in a very cost-effective tool in our hands.”

Damià Heine Suñer, PhD

Molecular Geneticist Molecular Diagnostics and Clinical Genetics Unit Hospital Universitari Son Espases

Mallorca, Spain